Grünenthal plants in South America will get $87M in upgrades
AACHEN, Germany and TOKYO, Aug. 2, 2023 /PRNewswire/ -- Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
Grünenthal GmbH (the “Company”) today announced the pricing of €300 million aggregate principal amount of 6.75% senior secured notes due 2030 (the “Notes”). The Notes will be issued at 100%. The Notes were offered outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). In the United States, the Notes were offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act.
The Japanese drugmaker will spin its international established medicines portfolio into a new joint venture with German company Grünenthal. The franchise includes 13 brands in the Europe, Middle East and Africa (EMEA) region, according to Kyowa Kirin.
AACHEN, Germany & TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. The Joint Venture Collaboration is subject to obtaining customary approvals and clearances, including anti-trust and works councils as legally required. Completion of the deal is anticipated for Q2 2023.
AACHEN, Germany, Nov. 2, 2022 /PRNewswire/ -- Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million.
According to people familiar with the matter, Grünenthal is nearing a deal to buy some of Japanese specialty pharmaceutical firm Kyowa Kirin's international assets, reported Bloomberg.
Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX...
Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin...
Frankfurt: German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation.